Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605
Recruiting
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Galderma Investigational Site - 8893, Birmingham, Alabama +110 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT04995523
Recruiting
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/15/2025
Locations: Research Site, Orange, California +47 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Recruiting
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Birmingham, Alabama +27 locations
Conditions: Acute Hepatic Porphyria
Register for Updates
Safe and Timely Antithrombotic Removal (STAR) Registry
NCT05077124
Recruiting
This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Universitätsklinikum Graz, Graz, Not set +29 locations
Conditions: Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
Register for Updates
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: Cullman Clinical Trials, Cullman, Alabama +40 locations
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712
Recruiting
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Sacramento, California +38 locations
Conditions: Cerebral Amyloid Angiopathy
Register for Updates
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814
Recruiting
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Research Site, Fayetteville, Arkansas +287 locations
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
Recruiting
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2025
Locations: Site Number - 1036, Phoenix, Arizona +42 locations
Conditions: Graves' Disease
Register for Updates
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226
Recruiting
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/14/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +95 locations
Conditions: Sickle Cell Disease, Thalassemia
Register for Updates
Mentalization-Based Therpay With Older Adults
NCT07065071
Recruiting
The investigators would like to find out if Mentalization-Based Therapy (MBT) is effective for people aged 60+ who struggle in relationships. The study aims to understand whether MBT helps older people to build better relationships and feel better about themselves. There is currently no research with people over 60 and MBT, yet MBT is being offered to the older adult population by NHS trusts throughout the UK without evidence for its effectiveness. As well as developing knowledge about how MBT c... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/14/2025
Locations: Derbyshire Healthcare NHS Foundation Trust, Derby, Derbyshire
Conditions: Mentalisation, Mentalization, Later Life, Older Adults, Attachment, Borderline Personality Disorder
Register for Updates
Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05997615
Recruiting
The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2). * Part 1 (Monotherapy Dose Escalation): Single-agent AMX-500 dose escalation * Part 2 (Monotherapy Dose Expansion): Single-agent AMX-500 dose expansion The study may subsequently continue via a protocol amendment with dose escalation of AMX-500 combinations (Part 3) followed by combination therapy dose expansion (Part 4).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Investigational Site Number: 101, New South Wales, Not set +7 locations
Conditions: Hormone-refractory Prostate Cancer
Register for Updates
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083
Recruiting
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
07/14/2025
Locations: Belite Study Site - US08, Phoenix, Arizona +13 locations
Conditions: STGD1, Stargardt Disease 1
Register for Updates